<p>McAdam LLC 在第一季度收购了 Axsome Therapeutics, Inc. (NASDAQ:AXSM - 免费报告) 的新股份，具体信息在该公司最近向 SEC 提交的文件中披露。该公司收购了 2,194 股，价值约为 256,000 美元。</p>
<ul>
<li>5 只医疗股票的收益增长超过三位数</li>
</ul>
<p>其他机构投资者和对冲基金最近也增加或减少了对该公司的持股。凯通国际资产管理有限公司在第一季度购买了价值约 25,000 美元的 Axsome Therapeutics 新股份。Quantbot Technologies LP 在第一季度购买了价值约 31,000 美元的 Axsome Therapeutics 新股份。NBC Securities Inc. 在第一季度购买了价值约 31,000 美元的 Axsome Therapeutics 新股份。AlphaQuest LLC 在第一季度购买了价值约 38,000 美元的 Axsome Therapeutics 新股份。最后，Neo Ivy Capital Management 在第一季度购买了价值约 41,000 美元的 Axsome Therapeutics 新股份。机构投资者持有该公司 81.49% 的股份。</p>
<p>获取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师的看法</h2>
<p>几位股票研究分析师最近对该股票发表了评论。HC Wainwright 在 6 月 10 日的报告中重申了 “买入” 评级，并对 Axsome Therapeutics 的股票设定了 180.00 美元的目标价。Oppenheimer 在 6 月 3 日的报告中开始覆盖 Axsome Therapeutics 的股票。他们对该公司给予了 “跑赢大盘” 的评级，并设定了 185.00 美元的目标价。加拿大皇家银行在 8 月 5 日的报告中将 Axsome Therapeutics 的目标价从 184.00 美元上调至 189.00 美元，并给予该公司 “跑赢大盘” 的评级。富国银行在 9 月 3 日的研究报告中将 Axsome Therapeutics 的评级提升至 “强力买入”。最后，Needham &amp; Company LLC 在 8 月 4 日的研究报告中重申了 “买入” 评级，并对 Axsome Therapeutics 的股票设定了 150.00 美元的目标价。两位投资分析师对该股票给予了强力买入评级，十三位分析师对该公司的股票给予了买入评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “买入”，平均目标价为 177.86 美元。</p>
<ul>
<li>处于困境的 Axsome 股票可能因药物试验成功而反弹</li>
</ul>
<p><strong>阅读我们对 Axsome Therapeutics 的最新分析</strong></p>
<h2>Axsome Therapeutics 的内部活动</h2>
<p>在 Axsome Therapeutics 的其他新闻中，首席法律顾问 Hunter R. Murdock 在 6 月 23 日的交易中出售了 6,014 股公司的股票。该股票的平均售价为 100.12 美元，总交易额为 602,121.68 美元。该交易在向 SEC 提交的文件中披露，文件可在此链接查看。此外，董事 Mark Coleman 在 9 月 8 日的交易中购买了 1,575 股公司的股票。该股票的平均购买成本为每股 127.28 美元，总交易额为 200,466.00 美元。交易后，该董事在公司持有 48,212 股，价值 6,136,423.36 美元。此次交易使其持股增加了 3.38%。该购买的披露信息可在此查看。内部人士在上个季度共出售了价值 11,766,554 美元的 100,299 股公司股票。目前，22.30% 的股票由公司内部人士持有。</p>
<h2>Axsome Therapeutics 股票下跌 0.9%</h2>
<ul>
<li>为什么现在是购买 Axsome Therapeutics 的绝佳时机</li>
</ul>
<p>NASDAQ:AXSM 周五开盘价为 122.96 美元。该公司的市值为 61.4 亿美元，市盈率为 -24.25，贝塔值为 0.54。Axsome Therapeutics, Inc. 的 12 个月低点为 75.56 美元，12 个月高点为 139.13 美元。该公司的流动比率为 1.57，速动比率为 1.51，债务与股本比率为 1.66。该公司的 50 日移动平均线为 111.93 美元，200 日移动平均线为 110.87 美元。</p>
<p>Axsome Therapeutics (NASDAQ:AXSM - 获取免费报告) 最近于 8 月 4 日发布了其财报。该公司报告本季度每股收益为 -0.92，超过了市场共识预期的 -1.00，超出幅度为 0.08。该公司本季度的收入为 1.5004 亿美元，而市场共识预期为 1.4002 亿美元。Axsome Therapeutics 的净利润率为 -49.88%，股本回报率为 -283.22%。分析师预计 Axsome Therapeutics, Inc. 本年度每股收益将为 -2.79。</p>
<h2>Axsome Therapeutics 公司简介</h2>
<p>(免费报告)</p>
<p>Axsome Therapeutics, Inc. 是一家生物制药公司，专注于开发针对中枢神经系统 (CNS) 疾病的新疗法。该公司的商业产品组合包括 Auvelity（右美沙芬 - 布普洛尼），这是一种具有多重作用的 N-甲基-D-天冬氨酸受体拮抗剂，适用于治疗重度抑郁症；以及 Sunosi（索利安非特），这是一种用于治疗嗜睡症或阻塞性睡眠呼吸暂停患者的药物。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 Axsome Therapeutics</li>
<li>想在下跌趋势中获利？下跌趋势解析。</li>
<li>接近阻力的高飞股票：3 只值得关注的股票</li>
<li>3 只值得长期持有的 REITs</li>
<li>希捷科技引领 S&amp;P 500：其 120% 的涨幅背后是什么？</li>
<li>公用事业股票解析 – 如何以及为何投资公用事业</li>
<li>先锋的 VUG ETF：您投资组合的终极增长 ETF</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
<h2>现在您应该投资 1,000 美元在 Axsome Therapeutics 吗？</h2>
<p>在考虑 Axsome Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Axsome Therapeutics 并不在名单上。</p>
<p>虽然 Axsome Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AXSM

<p>McAdam LLC 已经收购了 Axsome Therapeutics, Inc.（纳斯达克代码：AXSM）的新股份，购买了 2,194 股，价值约为 256,000 美元。其他机构投资者也增加了他们的持股。分析师对该股票给予了 “买入” 的共识评级，平均目标价为 177.86 美元。尽管最近股价下跌了 0.9%，Axsome 仍报告了超出预期的收益，上一季度的收入为 1.5004 亿美元。该公司继续开发针对中枢神经系统疾病的疗法</p>

<p>McAdam LLC acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 2,194 shares of the company's stock, valued at approximately $256,000.</p>
<div class="lb-trans"><p>McAdam LLC 在第一季度收购了 Axsome Therapeutics, Inc. (NASDAQ:AXSM - 免费报告) 的新股份，具体信息在该公司最近向 SEC 提交的文件中披露。该公司收购了 2,194 股，价值约为 256,000 美元。</p>
</div><ul>
<li>5 medical stocks growing earnings by triple digits</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只医疗股票的收益增长超过三位数</li>
</ul>
</div><p>Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of Axsome Therapeutics in the 1st quarter valued at about $25,000. Quantbot Technologies LP bought a new stake in shares of Axsome Therapeutics in the 1st quarter valued at about $31,000. NBC Securities Inc. bought a new stake in shares of Axsome Therapeutics in the 1st quarter valued at about $31,000. AlphaQuest LLC bought a new stake in shares of Axsome Therapeutics in the 1st quarter valued at about $38,000. Finally, Neo Ivy Capital Management bought a new stake in shares of Axsome Therapeutics in the 1st quarter valued at about $41,000. Institutional investors own 81.49% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也增加或减少了对该公司的持股。凯通国际资产管理有限公司在第一季度购买了价值约 25,000 美元的 Axsome Therapeutics 新股份。Quantbot Technologies LP 在第一季度购买了价值约 31,000 美元的 Axsome Therapeutics 新股份。NBC Securities Inc. 在第一季度购买了价值约 31,000 美元的 Axsome Therapeutics 新股份。AlphaQuest LLC 在第一季度购买了价值约 38,000 美元的 Axsome Therapeutics 新股份。最后，Neo Ivy Capital Management 在第一季度购买了价值约 41,000 美元的 Axsome Therapeutics 新股份。机构投资者持有该公司 81.49% 的股份。</p>
</div><p>Get <strong>Axsome Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>Several equities research analysts have recently commented on the stock. HC Wainwright restated a &#34;buy&#34; rating and issued a $180.00 price target on shares of Axsome Therapeutics in a report on Tuesday, June 10th. Oppenheimer assumed coverage on shares of Axsome Therapeutics in a report on Tuesday, June 3rd. They issued an &#34;outperform&#34; rating and a $185.00 price target for the company. Royal Bank Of Canada boosted their price target on shares of Axsome Therapeutics from $184.00 to $189.00 and gave the company an &#34;outperform&#34; rating in a report on Tuesday, August 5th. Wells Fargo &amp; Company raised shares of Axsome Therapeutics to a &#34;strong-buy&#34; rating in a research report on Wednesday, September 3rd. Finally, Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and issued a $150.00 price objective on shares of Axsome Therapeutics in a research report on Monday, August 4th. Two investment analysts have rated the stock with a Strong Buy rating and thirteen have issued a Buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of &#34;Buy&#34; and an average price target of $177.86.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该股票发表了评论。HC Wainwright 在 6 月 10 日的报告中重申了 “买入” 评级，并对 Axsome Therapeutics 的股票设定了 180.00 美元的目标价。Oppenheimer 在 6 月 3 日的报告中开始覆盖 Axsome Therapeutics 的股票。他们对该公司给予了 “跑赢大盘” 的评级，并设定了 185.00 美元的目标价。加拿大皇家银行在 8 月 5 日的报告中将 Axsome Therapeutics 的目标价从 184.00 美元上调至 189.00 美元，并给予该公司 “跑赢大盘” 的评级。富国银行在 9 月 3 日的研究报告中将 Axsome Therapeutics 的评级提升至 “强力买入”。最后，Needham &amp; Company LLC 在 8 月 4 日的研究报告中重申了 “买入” 评级，并对 Axsome Therapeutics 的股票设定了 150.00 美元的目标价。两位投资分析师对该股票给予了强力买入评级，十三位分析师对该公司的股票给予了买入评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “买入”，平均目标价为 177.86 美元。</p>
</div><ul>
<li>Struggling Axsome Stock Could Bounce Back on Drug Trial Success</li>
</ul>
<div class="lb-trans"><ul>
<li>处于困境的 Axsome 股票可能因药物试验成功而反弹</li>
</ul>
</div><p><strong>Read Our Latest Analysis on Axsome Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Axsome Therapeutics 的最新分析</strong></p>
</div><h2>Insider Activity at Axsome Therapeutics</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 的内部活动</h2>
</div><p>In other Axsome Therapeutics news, General Counsel Hunter R. Murdock sold 6,014 shares of the business's stock in a transaction that occurred on Monday, June 23rd. The shares were sold at an average price of $100.12, for a total transaction of $602,121.68. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Mark Coleman bought 1,575 shares of the company's stock in a transaction on Monday, September 8th. The shares were bought at an average cost of $127.28 per share, for a total transaction of $200,466.00. Following the transaction, the director owned 48,212 shares in the company, valued at $6,136,423.36. The trade was a 3.38% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 100,299 shares of company stock worth $11,766,554 in the last quarter. 22.30% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在 Axsome Therapeutics 的其他新闻中，首席法律顾问 Hunter R. Murdock 在 6 月 23 日的交易中出售了 6,014 股公司的股票。该股票的平均售价为 100.12 美元，总交易额为 602,121.68 美元。该交易在向 SEC 提交的文件中披露，文件可在此链接查看。此外，董事 Mark Coleman 在 9 月 8 日的交易中购买了 1,575 股公司的股票。该股票的平均购买成本为每股 127.28 美元，总交易额为 200,466.00 美元。交易后，该董事在公司持有 48,212 股，价值 6,136,423.36 美元。此次交易使其持股增加了 3.38%。该购买的披露信息可在此查看。内部人士在上个季度共出售了价值 11,766,554 美元的 100,299 股公司股票。目前，22.30% 的股票由公司内部人士持有。</p>
</div><h2>Axsome Therapeutics Stock Down 0.9%</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 股票下跌 0.9%</h2>
</div><ul>
<li>Why this is an Awesome Time to Buy Axsome Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么现在是购买 Axsome Therapeutics 的绝佳时机</li>
</ul>
</div><p>NASDAQ:AXSM opened at $122.96 on Friday. The company has a market cap of $6.14 billion, a PE ratio of -24.25 and a beta of 0.54. Axsome Therapeutics, Inc. has a twelve month low of $75.56 and a twelve month high of $139.13. The company has a current ratio of 1.57, a quick ratio of 1.51 and a debt-to-equity ratio of 1.66. The company's 50 day moving average is $111.93 and its two-hundred day moving average is $110.87.</p>
<div class="lb-trans"><p>NASDAQ:AXSM 周五开盘价为 122.96 美元。该公司的市值为 61.4 亿美元，市盈率为 -24.25，贝塔值为 0.54。Axsome Therapeutics, Inc. 的 12 个月低点为 75.56 美元，12 个月高点为 139.13 美元。该公司的流动比率为 1.57，速动比率为 1.51，债务与股本比率为 1.66。该公司的 50 日移动平均线为 111.93 美元，200 日移动平均线为 110.87 美元。</p>
</div><p>Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($0.92) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.08. The company had revenue of $150.04 million for the quarter, compared to the consensus estimate of $140.02 million. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. Analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.</p>
<div class="lb-trans"><p>Axsome Therapeutics (NASDAQ:AXSM - 获取免费报告) 最近于 8 月 4 日发布了其财报。该公司报告本季度每股收益为 -0.92，超过了市场共识预期的 -1.00，超出幅度为 0.08。该公司本季度的收入为 1.5004 亿美元，而市场共识预期为 1.4002 亿美元。Axsome Therapeutics 的净利润率为 -49.88%，股本回报率为 -283.22%。分析师预计 Axsome Therapeutics, Inc. 本年度每股收益将为 -2.79。</p>
</div><h2>Axsome Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.</p>
<div class="lb-trans"><p>Axsome Therapeutics, Inc. 是一家生物制药公司，专注于开发针对中枢神经系统 (CNS) 疾病的新疗法。该公司的商业产品组合包括 Auvelity（右美沙芬 - 布普洛尼），这是一种具有多重作用的 N-甲基-D-天冬氨酸受体拮抗剂，适用于治疗重度抑郁症；以及 Sunosi（索利安非特），这是一种用于治疗嗜睡症或阻塞性睡眠呼吸暂停患者的药物。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Axsome Therapeutics</li>
<li>Want to Profit on the Downtrend? Downtrends, Explained.</li>
<li>High-Flyers Near Resistance: 3 Stocks to Watch for a Dip</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>Seagate Technology Leads S&amp;P 500: What’s Behind Its 120% Gain?</li>
<li>Utilities Stocks Explained – How and Why to Invest in Utilities</li>
<li>Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Axsome Therapeutics</li>
<li>想在下跌趋势中获利？下跌趋势解析。</li>
<li>接近阻力的高飞股票：3 只值得关注的股票</li>
<li>3 只值得长期持有的 REITs</li>
<li>希捷科技引领 S&amp;P 500：其 120% 的涨幅背后是什么？</li>
<li>公用事业股票解析 – 如何以及为何投资公用事业</li>
<li>先锋的 VUG ETF：您投资组合的终极增长 ETF</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AXSM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Axsome Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>现在您应该投资 1,000 美元在 Axsome Therapeutics 吗？</h2>
</div><p>Before you consider Axsome Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Axsome Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Axsome Therapeutics 并不在名单上。</p>
</div><p>While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Axsome Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

McAdam LLC 在 Axsome Therapeutics, Inc.（股票代码：AXSM）中获得了新的持仓